Post by Grifols

Working to innovate for alpha-1 patients 💙 Grifols has officially dosed the first participant in SWIFT‑SC, a Phase 3 clinical trial evaluating a first‑of‑its‑kind subcutaneous (SC) formulation of Alpha1‑Proteinase Inhibitor for people living with alpha1‑antitrypsin (AAT) deficiency, or alpha-1. This global, open‑label study will compare 2 different weekly doses of subcutaneous Alpha-15% with corresponding standard intravenous Alpha1-PI doses.  🌟 Why this matters: Subcutaneous administration of medicines may provide meaningful benefits for patients including the possibility of self-administration and fewer clinic visits - providing greater flexibility in when and where treatment is administered. This builds on Grifols’ long-standing commitment to the alpha-1 patient community and to reaching those yet to be diagnosed. Learn more 👉 https://lnkd.in/e_2K4Gzy   #WeAreHealthcare #Alpha1Awareness #geneticcopd